Research programme: anti-transforming growth factor beta antibodies- XOMA Corporation/NovartisAlternative Names: XOMA-089
Latest Information Update: 10 Oct 2015
At a glance
- Originator XOMA
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators; Transforming growth factor beta1 inhibitors; Transforming growth factor beta2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Fibrosis
Highest Development Phases
- Preclinical Cancer; Fibrosis